Akebia Therapeutics, Inc. (AKBA) Announces Completion Of Enrollment In Its Phase 2b Clinical Study Of AKB-6548
4/15/2014 8:59:54 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by